HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 23, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the European Society for Medical Oncology (“ESMO”) Congress 2026, taking place on October 23-27, 2026, in Madrid, Spain.

Notably, results from two positive Phase III studies evaluating the savolitinib and osimertinib combination have been selected for oral presentations. Results from the global SAFFRON study will be featured in the Presidential Symposium session, while results from the SANOVO study in China will be presented in a Proffered Paper session, both highlighting important new clinical data. Having two Phase III studies featured as late-breaking abstracts underscores the potential of this all-oral, chemo-free combination to deliver meaningful advancements for patients with non-small cell lung cancer (“NSCLC”).

The SAFFRON Global Phase III Study has been selected for a Presidential Symposium oral presentation. The study evaluated the combination in patients with epidermal growth factor receptor (EGFR)-mutated NSCLC with MET overexpression or amplification following disease progression on osimertinib. The trial reported positive high-level results on August 17, 2026, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (“PFS”) and overall survival (“OS”) compared to doublet platinum-based chemotherapy.

The SANOVO China Phase III Study has been selected for a Proffered Paper oral presentation. The study evaluated the combination in previously untreated patients with locally advanced or metastatic NSCLC harboring activating EGFR mutations and MET overexpression. The trial reported positive high-level results on August 31, 2026, demonstrating a statistically significant and clinically meaningful improvement in PFS and a clinically meaningful benefit in OS versus osimertinib monotherapy.

Details of the presentations are as follows:

Abstract title Presenter / Lead author Presentation details
     
SPONSORED STUDIES    
Osimertinib (osi) + savolitinib (savo) vs platinum–pemetrexed (plat–pem) in EGFRm MET-overexpressed (OE) and/or -amplified (AMP) advanced NSCLC post-osi: SAFFRON Phase (Ph) 3 primary results Shun Lu
(Shanghai, China)
LBA6
Presidential Symposium II
Alicante Auditorium – Hall 6
Sunday, October 25, 2026
16:30 – 18:15 CEST
Savolitinib or Placebo Combined with Osimertinib in Treatment-Naïve Advanced NSCLC with EGFR Mutation and MET Overexpression: Results from the Phase 3 SANOVO Study Yi-Long Wu
(Guangzhou, China)
LBA69
Proffered paper 2: NSCLC, metastatic
Alicante Auditorium – Hall 6
Monday, October 26, 2026
08:30 – 10:00 CEST
Updated results from a fruquintinib Expanded Access Program for patients with previously treated metastatic colorectal cancer Stefan Kasper
(Essen, Germany)
848P
Poster Session: Colon cancer
Association between dose adjustment and treatment outcomes in patients with advanced renal cell carcinoma receiving fruquintinib plus sintilimab: A post-hoc analysis of the FRUSICA-2 trial Yuanyuan Qu
(Shanghai, China)
3655eP
E-poster Session: Renal cancer
Efficacy of fruquintinib plus sintilimab in special populations with advanced renal cell carcinoma: A subgroup analysis of FRUSICA-2 study Kaiwei Yang
(Beijing, China)
3667eP
E-poster Session: Renal cancer
Final phase 2 analysis of surufatinib plus camrelizumab, nab-paclitaxel and gemcitabine in first-line metastatic pancreatic cancer Shukui Qin
(Nanjing, China)
3156P
Poster Session: Pancreatic cancer
     
INVESTIGATOR-INITIATED STUDIES    
Fruquintinib plus capecitabine maintenance after first-line anti-EGFR antibody plus chemotherapy in RAS/BRAF wild-type metastatic colorectal cancer: A phase Ib/II study Lin Yang/ Letian Zhang
(Beijing, China)
877eP
E-poster Session: Colon cancer
Real-world effectiveness and safety of fruquintinib in patients with metastatic colorectal cancer in Spain: The FrESP study Ana Fernandez Montes
(Ourense, Spain)
880eP
E-poster Session: Colon cancer
CONCEPT (COmbinatioN of CEtuximab Plus fruquintinib Treatment ± immunotherapy): A multicenter, randomized, open-label phase II trial in first-line pMMR RAS/BRAF wild-type unresectable metastatic colorectal cancer Kefeng Ding
(Hangzhou, China)
890eP
E-poster Session: Colon cancer
A real-world study of low-dose fruquintinib combined with trifluridine/tipiracil hydrochloride (TAS-102) in the third-line and beyond treatment of metastatic colorectal cancer Yuehong Cui/ Li Liang
(Shanghai, China)
903eP
E-poster Session: Colon cancer
Real-world outcomes with fruquintinib in heavily pretreated metastatic colorectal cancer: Impact of patient and disease characteristics Maria Maddalena
Laterza (Pozzuoli, Italy)
964eP
E-poster Session: Colon cancer
A phase II, open-label, randomized study of doublet chemotherapy (FOLFOX or FOLFIRI) plus fruquintinib compared with doublet chemotherapy (FOLFOX or FOLFIRI) plus bevacizumab in second line setting for a metastatic colorectal cancer: ULYSSE- FFCD2406 – PRODIGE115 (trials in progress) Jean Marc Phelip
(Saint-Étienne, France)
991eTiP
E-poster Session: Colon cancer
Phase II study of fruquintinib plus utidelone in platinum-resistant recurrent ovarian cancer (FRUTD Trial) Zheng Feng
(Shanghai, China)
1283P
Poster Session: Gynaecological cancers
Fruquintinib plus eribulin in patients with metastatic HR+, HER2–breast cancer after progression on endocrine therapy plus CDK4/6 inhibitor: Updated results from a phase II study Yuan Yuan
(Nanjing, China)
1896eP
E-poster Session: HR+ breast cancer
Fruquintinib plus sintilimab and XELOX as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, open-label, multicenter phase II study Hua Wang
(Nanchang, China)
2980eP
E-poster Session: Oesophagogastric cancer
Fruquintinib plus cadonilimab and S-1 in previously treated unresectable locally advanced or metastatic esophageal squamous cell carcinoma: preliminary efficacy and safety results from a phase Ib/II study Huiyan Luo
(Guangzhou, China)
2981eP
E-poster Session: Oesophagogastric cancer
Nanoliposomal irinotecan (nal-IRI) combined with fruquintinib as second-line treatment for advanced gastric cancer: A single-arm, open-label, dose-escalation and expansion phase I/II trial Jieer Ying/ Qi Xu
(Hangzhou, China)
2986eP
E-poster Session: Oesophagogastric cancer
FRUQUITAS trial: ENGIC intergroup randomized phase III of trifluridine/tipiracil +/- fruquintinib in pre-treated metastatic gastro-oesophageal adenocarcinoma David Tougeron (Poitiers, France) 3079eTiP
E-poster Session: Oesophagogastric cancer
CHOICE III: short-course preoperative radiotherapy followed by fruquintinib plus anti–PD-1 antibody (serplulimab) for neoadjuvant treatment of pMMR/MSS mid-to-low locally advanced rectal cancer: A single-arm, single-center, prospective phase II study Wei Zhang
(Shanghai, China)
3582eTiP
E-poster Session: Rectal and anal cancer
First-line fruquintinib plus serplulimab for metastatic non-clear cell renal cell carcinoma: Updated results from the phase II FRONTIER study Jiwei Huang
(Shanghai, China)
3614P
Poster Session: Renal cancer
Latest efficacy and safety analysis of surufatinib combined with EP regimen and serplulimab as first-line treatment for extrapulmonary neuroendocrine carcinoma Tao Zhang/ Zhenyu Lin
(Wuhan, China)
2394RO
Rapid Oral Session: NETs and endocrine tumours
Pamplona Auditorium – Hall 5
Friday, October 23, 2026
16:15 – 17:45 CEST
Surufatinib combined with toripalimab and nab-paclitaxel/ gemcitabine chemotherapy as first-line treatment for advanced pancreatobiliary-type ampullary carcinoma: A prospective phase II Clinical Trial Juan Du
(Nanjing, China)
507eP
E-poster Session: Biliary tract cancer, incl. cholangiocarcinoma
Efficacy and safety of surufatinib in combination with CAPTEM in advanced G2/G3 Neuroendocrine Tumors: Results from a single-arm, phase II Trial Wei Wang
(Guangzhou, China)
2403P
Poster Session: Neuroendocrine tumours
Surufatinib plus S-1/temozolomide as first-line therapy in MGMT-low advanced pancreatic neuroendocrine tumours (SUSTEM-p): An open-label, single-centre phase Ib/II trial Yihebali Chi
(Beijing, China)
2411P
Poster Session: Neuroendocrine tumours
Updated results of a prospective, open-label study of surufatinib plus CAPTEM as conversion therapy for unresectable pancreatic neuroendocrine tumors Ziyao Wang
(Chengdu, China)
2412P 
Poster Session: Neuroendocrine tumours
Matching-adjusted indirect comparison of surufatinib versus high-dose OCT-LAR in patients with advanced GEP-NETs who progressed on prior SSA Therapy Jianming Xu
(Beijing, China)
2415P
Poster Session: Neuroendocrine tumours
Surufatinib combined with octreotide LAR for the treatment of G1/G2 GEP-NETs: A single-arm, prospective, open-label phase II study Xiaofeng Sun
(Nanjing, China)
2439eP
E-poster Session: Neuroendocrine tumours
Six weeks of induction gemcitabine plus nab paclitaxel (AG) followed by sequential surufatinib plus AG or AG alone as first line therapy for locally advanced or metastatic pancreatic ductal adenocarcinoma (mPDAC): A single center, two cohort, phase II study Jin Xu/ Jialin Li
(Shanghai, China)
3168P
Poster Session: Pancreatic cancer
A phase Ib/II study of radiotherapy combined with surufatinib and sintilimab for localized high-risk limb and trunk soft tissue sarcomas: A prospective single-center trial Yan Wang
(Shanghai, China)
3739P
Poster Session: Sarcoma
Surufatinib plus serplulimab, etoposide, and carboplatin as first-line treatment for extensive-stage small cell lung cancer (ES-SCLC): Updated results from a single-arm, phase Ia/Ib trial Haipeng Xu/ Longfeng Zhang
(Fuzhou, China)
3831P
Poster Session: Small cell lung cancer


About Fruquintinib
Fruquintinib is a selective oral inhibitor of all three vascular endothelial growth factor receptors (“VEGFR”) -1, -2 and -3. Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE®. Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA®.

About Savolitinib
Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. Savolitinib is being jointly developed by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca under the brand name ORPATHYS®.

About Surufatinib
Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with VEGFRs and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells. Surufatinib is marketed in China by HUTCHMED under the brand name SULANDA®. HUTCHMED currently retains all rights to surufatinib worldwide.

About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of fruquintinib, surufatinib and savolitinib, the further clinical development for fruquintinib, surufatinib and savolitinib, its expectations as to whether any studies on fruquintinib, surufatinib and savolitinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of fruquintinib, surufatinib and savolitinib, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of fruquintinib, surufatinib and savolitinib for a targeted indication, and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products such as sintilimab and toripalimab as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

Investor Enquiries +852 2121 8200 / ir@hutch-med.com
   
Media Enquiries  
FTI Consulting – +44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
   
Panmure Liberum Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden +44 20 7886 2500
   
Cavendish Joint Broker
Geoff Nash / Nigel Birks +44 20 7220 0500
   
Deutsche Numis Joint Broker
Duncan Monteith / Ramin Naji +44 20 7545 8000

EssilorLuxottica and Meta further advance AI glasses category
with new products revealed at Meta Connect

The two companies introduce new line of audio AI glasses and next generation of
Ray-Ban Meta, the world’s leading AI glasses

Paris, France and Menlo Park, California (24 September 2026) – EssilorLuxottica and Meta Platforms, the partnership behind the fast-growing smart eyewear category, unveiled the next generation of AI glasses at Meta Connect. Expanding their groundbreaking portfolio of products, the companies announced a new line of audio glasses, a third generation of Ray-Ban Meta, as well as new models, features and geographies for existing products. By the end of this year, the companies will offer more than 100 different styles of AI glasses. And they announced Meta’s new personal AI agent, Muse, will be coming to AI glasses.

Ray-Ban Meta Audio: Given that audio is consistently Ray-Ban Meta’s most popular feature, particularly because the glasses deliver high-quality sound without having to close off the world around you, the companies have introduced Ray-Ban Meta Audio, a camera-free line of AI glasses, their lightest and slimmest yet, weighing as low as 43 grams, offering maximum comfort with professional-adjustable temple tips, adjustable or swappable nose pads and overextension hinges ensuring a perfect fit for all-day wear. Ray-Ban Meta Audio will launch in two new styles: Clubmaster and Burbank, both compatible with a wide range of optical prescriptions. 

Ray-Ban Meta Gen 3: Also unveiled at Meta Connect was the next generation of the world’s leading AI glasses: Ray-Ban Meta Gen 3 comes in a slimmer, more comfortable design with longer battery life and a customizable action button for instant access to Meta AI. The Gen 3 collection, which comes in 27 color and lens combinations, will now include one of the most legendary silhouettes, the Aviator, which is celebrating its 90th anniversary, making it a milestone moment for the brand. The collection will also include Zena, a bold new style with a distinctive and modern cat eye look, and the iconic Wayfarer in both standard and large sizes.

Opening the category to new audiences: Meta Glasses with EssilorLuxottica are also expanding with two new styles – Capri and Nova – to offer a wider consumer choice and introducing also two new models designed with the international icon, LISA. These round out the most expansive and accessible portfolio of AI glasses.

A richer AI glasses experience: Muse, a personal AI agent, is coming to all the companies’ AI glasses (available in US only), handling tasks hands-free so wearers can stay present. Capture also improves with Dynamic Photo and Landscape Crop Mode, alongside support for Dolby Atmos. Finally, Hearing Enhancement (available in US only), an FDA-cleared software feature for adults with perceived mild to moderate hearing loss, arrives via one-time payment or subscription later this year. Powering the next generation of AI capabilities with consumer privacy in mind, Meta will bring “private processing” to AI glasses later this year. The portfolio of AI glasses from EssilorLuxottica and Meta will welcome new features ranging from guided workouts and nutrition, expanding navigation with cycling and public transit directions.

Global retail expansion: EssilorLuxottica is bringing the already loved portfolio of AI glasses to more consumers, expanding in the coming months in these new markets: Poland, Portugal, Israel, South Africa, Indonesia, Thailand, Hong Kong, New Zealand, Malaysia and the Philippines. Additionally, Meta Ray-Ban Display are now available to purchase online and are expanding into five new markets. The glasses go on sale today in the UK and Canada. Pre-orders will progressively start from today in France, Italy and Germany, initially through select retail locations in Vancouver, Toronto, London, Paris, Milan, Rome, Frankfurt, Hamburg and Munich.

“From launching the original Ray-Ban Stories five years ago to building a powerful assortment of AI glasses with strong consumer choice across brands, price points and tech features, we’re proud of our pioneering role in the category. As we expand with new innovations that have long been in the works like Ray-Ban Meta Audio, and develop new use cases for glasses, our ability to anticipate and deliver on consumer needs and desires will grow even stronger,” commented Francesco Milleri, Chairman and CEO, EssilorLuxottica.

“AI glasses need to match people’s individual sense of style while looking and feeling great on every kind of face. Meta and EssilorLuxottica are working to make sure every person can find the right pair for them, and the products we announced today bring new options for everyone,” said Mark Zuckerberg, CEO, Meta.

Attachment

SALT LAKE CITY, Sept. 23, 2026 (GLOBE NEWSWIRE) — Medallion Bank (Nasdaq: MBNKO), an FDIC-insured bank providing consumer loans for the purchase of recreational vehicles, boats, and home improvements, along with loan origination services to fintech strategic partners, announced today that it has priced a public offering of 2,200,000 additional shares of its Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series G, par value $1.00 per share, with a liquidation amount of $25 per share (the “Series G Preferred Stock”) and an aggregate liquidation amount of $55,000,000. The offering is a reopening of Medallion Bank’s original issuance of its Series G Preferred Stock, which occurred on May 22, 2025.

Dividends will accrue on the liquidation amount of $25 per share of the Series G Preferred Stock at a fixed rate per annum equal to (i) 9.00% from the original issue date of the Series G Preferred Stock to, but excluding, July 1, 2030, and (ii) from and including July 1, 2030, at a rate equal to the five-year U.S. Treasury rate plus 4.94% per annum. Dividends will be payable in arrears on January 1, April 1, July 1 and October 1 of each year. In each case, dividends will be paid only when, as and if declared by the board of directors of Medallion Bank (or a duly authorized committee of the board) and to the extent Medallion Bank has legally available funds to pay dividends. Because the original issue date of the shares being offered will occur after the record date for the next Series G Preferred Stock dividend payment date on October 1, 2026, dividends on the offered shares, if declared, will accrue from October 1, 2026, and will be payable commencing on January 1, 2027.

Medallion Bank’s Series G Preferred Stock is traded on the Nasdaq Capital Market under the ticker symbol “MBNKO.” The underwriters have also been granted a 30-day option to purchase up to an additional 330,000 shares of the Series G Preferred Stock solely to cover over-allotments, if any. Medallion Bank will remain a wholly owned subsidiary of Medallion Financial upon completion of the offering.

Medallion Bank intends to use the net proceeds from this offering for general corporate purposes, which may include, among other things, redeeming some or all of its outstanding Senior Series E Non-Cumulative Perpetual Preferred Stock (the “Series E Preferred Stock”), subject to the prior approval of the Federal Deposit Insurance Corporation. The offering is expected to close on September 30, 2026, subject to customary closing conditions.

Piper Sandler & Co., Lucid Capital Markets, LLC, Muriel Siebert & Co., LLC, A.G.P. / Alliance Global Partners, and Ladenburg Thalmann & Co. Inc. are acting as joint book-running managers. William Blair & Company, L.L.C., InspereX LLC, B. Riley Securities, Inc., and Clear Street LLC are acting as lead managers.

The offering of the Medallion Bank’s Series G Preferred Stock is exempt from the registration requirements of the Securities Act of 1933 pursuant to Section 3(a)(2) of that Act and will be made only by means of an offering circular. This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. The securities are neither insured nor approved by the Federal Deposit Insurance Corporation or any other Federal or state regulatory body.

The preliminary offering circular relating to the offering is available at medallionbankoffering.com. In addition, copies of the preliminary offering circular may also be obtained from: Piper Sandler & Co.; Attn: Debt Capital Markets, 1251 Avenue of the Americas, 6th Floor, New York, 10020, or by email at fsg-dcm@psc.com.

About Medallion Bank

Medallion Bank specializes in providing consumer loans for the purchase of recreational vehicles, boats, and home improvements, along with loan origination services to fintech strategic partners. The Bank works directly with thousands of dealers, contractors and financial service providers serving their customers throughout the United States. Medallion Bank is a Utah-chartered, FDIC-insured industrial bank headquartered in Salt Lake City and is a wholly owned subsidiary of Medallion Financial Corp.
For more information, visit www.medallionbank.com

This press release contains “forward-looking statements”, which reflect Medallion Bank’s current views with respect to future events and which address matters that are, by their nature, inherently uncertain and beyond Medallion Bank’s control. These statements are often, but not always, made through the use of words or phrases such as “expect” and “intend” or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These statements relate to the offering of shares of the Series G Preferred Stock, the anticipated use of the net proceeds by Medallion Bank and the grant to the underwriters of an option to purchase additional shares of the Series G Preferred Stock. No assurance can be given that the transaction discussed above will be completed on the terms described, or at all, or that Medallion Bank will decide to redeem its Series E Preferred Stock or, if it does, the amount to be redeemed and the timing of redemption and required regulatory approval. Completion of the offering on the terms described, including the grant of the option to the underwriters, and the application of net proceeds, are subject to numerous conditions, many of which are beyond the control of Medallion Bank. Medallion Bank undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. For a description of certain risks to which Medallion Bank is or may be subject, please refer to the factors discussed under the headings “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors,” in Medallion Bank’s Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026.

This press release does not constitute a notice of redemption with respect to the Series E Preferred Stock.

Company Contact

Investor Relations

212-328-2176

investorrelations@medallion.com

LOS ANGELES, Sept. 23, 2026 (GLOBE NEWSWIRE) — Hanmi Financial Corporation (NASDAQ: HAFC, or “Hanmi”), and its wholly-owned subsidiary, Hanmi Bank (the “Bank”), today announced its inclusion in the Piper Sandler Sm-All Stars Class of 2026, recognizing the Bank’s strong financial performance and operating fundamentals. Only 25 institutions nationwide earned recognition in the 2026 class. This is the second time that Hanmi Bank has been recognized in the Piper Sandler Sm-All Stars.

Piper Sandler awards this designation annually to a select group of banks and thrifts with market capitalizations below $2.5 billion that exceed industry median performance in key measures of earnings growth, loan growth, deposit growth, and return on average equity, while also meeting stringent asset quality and capital standards.

“We are honored to be recognized by Piper Sandler as a member of its 2026 Sm-All Stars,” said Bonnie Lee, President and Chief Executive Officer. “We believe this recognition underscores our strong financial performance, which reflects the success of our customer relationship banking model, our disciplined approach to risk management, and the dedication of our employees. As we continue to execute our strategic priorities, we remain focused on delivering consistent performance and long-term value for our shareholders.”

About Hanmi Financial Corporation
Headquartered in Los Angeles, California, Hanmi Financial Corporation owns Hanmi Bank, which serves multi-ethnic communities through its network of 32 full-service branches, five loan production offices and three loan centers in California, Texas, Illinois, Virginia, New Jersey, New York, Colorado, Washington and Georgia. Hanmi Bank specializes in real estate, commercial, SBA and trade finance lending to small and middle market businesses. Additional information is available at www.hanmi.com.

Media Contact:
Kelly Hull
Financial Profiles, Inc.
khull@finprofiles.com
310-622-8252

Investor Contacts:
Romolo (Ron) Santarosa
Senior Executive Vice President & Chief Financial Officer
213-427-5636

Lisa Fortuna
Investor Relations
Financial Profiles, Inc.
lfortuna@finprofiles.com
310-622-8251

VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) — GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) (FSE: 4QS) (the “Company” or “GoldHaven”) is pleased to announce that it has closed a further tranche of its previously announced non-brokered flow-through financing (the “Flow-Through Offering”) through the issuance of 4,206,906 flow-through common shares (the “FT Shares”) at a price of $0.265 per FT Share for aggregate proceeds of $1,114,830.

With the completion of this tranche, GoldHaven has raised aggregate gross proceeds of approximately $3.0 million under the Flow-Through Offering.

The additional capital is expected to provide GoldHaven with increased financial flexibility to advance exploration at its Magno Project and build upon the Company’s ongoing 2026 exploration program.

Rob Birmingham, CEO of GoldHaven, commented: “We are very pleased with the strong support for this financing and the additional demand that allowed us to close approximately $3.0 million. This capital strengthens our ability to advance the exploration program at Magno and build on the momentum we have established on the ground. We appreciate the continued support from both existing and new investors as we move through this important phase of exploration.”

In connection with the closing, the Company paid cash finder’s fees totaling $27,825 and issued 105,000 non-transferable finder warrants (each, a “Finder Warrant”) to certain eligible arm’s-length finders who introduced subscribers to the Offering. Each Finder Warrant entitles the holder to purchase one common share (a “Finder Share”) at a price of $0.35 per Finder Share for a period of 24 months from the date of issuance. All securities issued pursuant to the Offering are subject to a statutory hold period expiring four months plus one day from closing, in accordance with applicable securities laws and Canadian Securities Exchange requirements.

USE OF PROCEEDS

The gross proceeds from the Offering will be used to incur eligible Canadian exploration expenses that will qualify as “Critical Mineral Mining Expenditures” as defined under the Income Tax Act (Canada). The expenditures will be renounced to subscribers effective December 31, 2026.

Funds from the Offering are expected to support ongoing exploration and advancement of the Company’s Magno Project.

On Behalf of the Board of Directors

Rob Birmingham, Chief Executive Officer

For further information, please contact:
Rob Birmingham, CEO
www.GoldHavenresources.com
info@goldhavenresources.com
Office Direct: (604) 629-8254

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE- Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements Regarding Forward Looking Information

This news release contains forward-looking statements and forward-looking information (collectively, “forward looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein including, without limitation, those listed below under the heading “Forward-Looking Statements in This News Release” are forward-looking statements. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: “believes”, “will”, “expects”, “anticipates”, “intends”, “estimates”, “plans”, “may”, “should”, “potential”, “scheduled”, or variations of such words and phrases and similar expressions, which, by their nature, refer to future events or results that may, could, would, might or will occur or be taken or achieved. In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, that there will be investor interest in future financings, market fundamentals will result in sustained precious metals demand and prices, the receipt of any necessary permits, licenses and regulatory approvals in connection with the future exploration and development of any future projects in a timely manner, the availability of financing on suitable terms for exploration and development of future projects and the Company’s ability to comply with environmental, health and safety laws.

The Company cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward-looking statements as a result of various factors, including, operating and technical difficulties in connection with mineral exploration and development activities, actual results of exploration activities, the estimation or realization of mineral reserves and mineral resources, the inability of the Company to obtain the necessary financing required to conduct its business and affairs, as currently contemplated, the inability of the Company to enter into definitive agreements in respect of possible Letters of Intent, the timing and amount of estimated future production, the costs of production, capital expenditures, the costs and timing of the development of new deposits, requirements for additional capital, future prices of precious metals, changes in general economic conditions, changes in the financial markets and in the demand and market price for commodities, lack of investor interest in future financings, accidents, labour disputes and other risks of the mining industry, delays in obtaining governmental approvals, permits or financing or in the completion of development or construction activities, changes in laws, regulations and policies affecting mining operations, title disputes, the inability of the Company to obtain any necessary permits, consents, approvals or authorizations, including by the Exchange, the timing and possible outcome of any pending litigation, environmental issues and liabilities, and risks related to joint venture operations, and other risks and uncertainties disclosed in the Company’s latest interim Management’s Discussion and Analysis and filed with certain securities commissions in Canada. All of the Company’s Canadian public disclosure filings may be accessed via www.sedarplus.ca and readers are urged to review these materials.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update any of the forward-looking statements. The Company undertakes no obligation to update any of the forward-looking statements in this news release or incorporated by reference herein, except as otherwise required by law.

Forward-Looking Statements in This News Release

The following statements in this news release constitute forward-looking information:

  • The expectation that the additional capital will provide GoldHaven with increased financial flexibility to advance exploration at its Magno Project and build upon the Company’s ongoing 2026 exploration program
  • GoldHaven’s plan to further strengthen its exploration program at Magno while maintaining the momentum established on the ground
  • The expenditures from the Offering being renounced to subscribers effective December 31, 2026

TORONTO, Sept. 23, 2026 (GLOBE NEWSWIRE) — BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the final September 2026 cash distributions for the iShares Premium Money Market ETF. Unitholders of record on September 24, 2026 will receive cash distributions payable on September 29, 2026.

Details regarding the final “per unit” distribution amounts are as follows:

Fund Name Fund Ticker Cash Distribution Per Unit
iShares Premium Money Market ETF CMR $0.093

Further information on the iShares ETFs can be found at http://www.blackrock.com/ca.

About BlackRock
BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate.

About iShares ETFs
iShares unlocks opportunity across markets to meet the evolving needs of investors. With more than twenty years of experience, a global line-up of more than 1,700 exchange traded funds (ETFs) and approximately $6.2 trillion in assets under management as of June 30, 2026, iShares continues to drive progress for the financial industry. iShares funds are powered by the expert portfolio and risk management of BlackRock.   

iShares® ETFs are managed by BlackRock Canada.

Commissions, trailing commissions, management fees and expenses all may be associated with investing in iShares ETFs. Please read the relevant prospectus before investing. The funds are not guaranteed, their values change frequently and past performance may not be repeated. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional.

Contact for Media:
Sydney Punchard
Email: Sydney.Punchard@blackrock.com

Vectus CEO Erik Prince confirms intent to purchase at least 40 Swarmer-built air defense systems in year one and 80 or more in year two following the start of production in Poland

AUSTIN, Texas, Sept. 23, 2026 (GLOBE NEWSWIRE) — Swarmer, Inc (“Swarmer”) (NASDAQ: SWMR), a drone autonomy platform company that has supported more than 100,000 real-world combat missions in Ukraine since April 2024, today announced it has signed a nonbinding memorandum of understanding with Vectus Air Defense Systems, a company in which Swarmer holds a 20% interest, to manufacture, sell and deploy end-to-end air defense systems in eligible markets, subject to applicable export-control, sanctions, procurement, and other governmental requirements.

Swarmer intends to establish an air defense system manufacturing facility in Poland. Under the memorandum, Vectus has confirmed its intent to purchase and deploy at least 40 Swarmer-built systems in year one and 80 or more in year two following the start of production.

“We intend to manufacture an end-to-end solution that includes radars, cameras, fire control and effectors to target a variety of threats, including newer jet-powered Shahed-type attack drones,” said Alex Fink, Swarmer U.S. CEO and president. “The systems use combat-proven Gatling-type rotary cannons, capable of firing 20mm rounds at a rate of up to 6,000 rounds per minute, as the last line of defense.”

Fink estimates each system will retail at approximately $5 million to $6 million. Gun-based kinetic effectors are intended to significantly reduce the cost per kill compared with multimillion-dollar precision-guided missiles. Historically, drones are much cheaper than the missiles used to intercept them, whereas 20mm ammunition is relatively inexpensive and widely available.

“In my experience, high-powered rotary cannons produce a wall of lead that few aerial threats can survive,” said Erik Prince, who acts as both Vectus’ CEO and Swarmer’s board chairman. “I believe these systems will be in high demand because they are portable, affordable and designed to destroy targets on impact. High-speed enemy drones may outfly an interceptor, but they can’t outfly thousands of 20mm rounds.”

Final quantities, pricing, financing, specifications, and delivery schedules remain subject to definitive agreements.

About Swarmer

Swarmer™ (Nasdaq: SWMR) is a defense technology company that specializes in vendor-agnostic software which allows one operator to intuitively control hundreds of autonomous platforms in real time. Swarmer’s primary mission areas include autonomous swarm coordination, integration of multi-domain unmanned systems and AI-powered autonomy software for distributed operations. Swarmer’s technology has been rigorously validated in real-world kinetic environments and was first deployed in combat operations in Ukraine in April 2024. Since then, it has completed more than 100,000 combat missions, generating terabytes of proprietary data that informs its machine-learning models and enables the replication of advanced pilot performance at scale. Swarmer’s routine use in combat missions generates continuous streams of telemetry, sensor data and operational feedback which are then used to refine performance, increase resilience and accelerate learning. Swarmer has headquarters in Austin, Texas, and maintains operations and teams in Ukraine, Poland and Estonia. For more information, visit www.swarmer.com.

About Vectus Air Defense Systems

Vectus Air Defense Systems provides Air Defense as a Service for sovereign governments and critical infrastructure operators. The company designs, integrates and continuously operates layered air-defense systems under multi-year service agreements, while monitoring evolving threats and upgrading deployed systems as technologies and tactics change. Its mission is to help ensure that critical infrastructure remains operational when disruption is not an option. For more information, visit: https://www.vectusairdefense.com.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements that are not historical facts, including statements concerning the negotiation and execution of definitive agreements between Swarmer and Vectus; the proposed establishment, timing, financing and operation of manufacturing operations in Poland; the anticipated development, manufacturing, pricing, commercial availability, sales, purchase, deployment, delivery, capabilities and performance of the air defense systems; Vectus’ intended purchases including anticipated quantities and timing; potential customer demand, cost savings and market opportunity; Swarmer’s product roadmap, commercialization plans, customer adoption, growth strategy and defense technology strategy; and any other statements using words such as “anticipate,” “believe,” “can,” “could,” “designed,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “seek,” “should,” “will,” “would” or similar expressions.

These forward-looking statements are based on current expectations, estimates, assumptions and beliefs and are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties include, among others: the risk that the nonbinding memorandum of understanding may be terminated or may not result in definitive agreements or binding purchase orders; the risk that Vectus may purchase fewer systems than currently contemplated or none at all; the risk that required financing, permits, regulatory approvals or governmental authorizations may not be obtained or may be subject to conditions; the risk that the proposed manufacturing operations in Poland may be delayed, reduced in scope or not established; the risk that final pricing, quantities, configurations, delivery schedules and other commercial terms may differ from current expectations; the risk that product development, testing, validation, commercial availability, production or deliveries may be delayed or unsuccessful; risks associated with sourcing and integrating radars, cameras, fire-control systems, effectors, ammunition and other third-party components; reliance on partners, suppliers, customers and government stakeholders; technical, operational, cybersecurity, safety and field-performance risks; the risks related to government, defense and international procurement processes; risks related to operating in or supporting customers in active conflict zones, including Ukraine; geopolitical, sanctions, export-control, defense-trade-control and other regulatory risks; competition in the defense technology sector; and the risk that the transactions and relationships described in this press release may not produce the anticipated operational, commercial, technical or strategic benefits.

Forward-looking statements speak only as of the date of this press release. Swarmer undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Additional risks and uncertainties are described in Swarmer’s filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in Swarmer’s registration statement and other filings filed with or furnished to the SEC.

Investor Contact (Swarmer): swmr@gateway-grp.com 

Media Contact (Swarmer): media@swarmer.tech 

Dr. Jennifer Billingsley Appointed President

PHOENIX, Sept. 23, 2026 (GLOBE NEWSWIRE) — Aspen Group, Inc. (“AGI”) (OTCQB: ASPU), an education technology holding company and the parent company of Aspen University (AU) and United States University (USU), announced today that Dr. Scott Burrus has resigned as President of USU and AU (the “Universities”), effective September 23, 2026. Dr. Jennifer Billingsley, DNP, FNP-BC, CNE, currently Provost and Chief Academic Officer of the Universities, has been appointed President, effective immediately.

Dr. Billingsley brings more than 20 years of experience in academic leadership, higher education and clinical practice to the role. As a member of the Aspen Group leadership team for over 8 years, she is currently serving in the role of Provost and Chief Academic Officer where she oversees USU’s and AU’s academic programs, student services, accreditation and faculty development. Dr. Billingsley previously served as Dean and Professor of USU’s College of Nursing and Health Sciences, where she helped launch the University’s first doctoral program, supported the Commission on Collegiate Nursing Education (“CCNE”) accreditation and led initiatives focused on student success and faculty development.

“Jennifer is an accomplished academic leader who has played an important role in the development of our institutions,” said Matt LaVay, Chief Executive Officer of Aspen Group. “Her deep knowledge of their academic programs and students, together with her experience in accreditation and academic leadership, makes her well suited to lead them through their next phase, including the pending merger of AU into USU. We look forward to working with Jennifer as we continue to advance our academic programs and support student success.”

LaVay continued, “On behalf of USU and AU, I would also like to thank Scott for his leadership and contributions to the Universities. During his tenure, Scott played an important role in the academic and institutional development of both institutions. We appreciate his service and wish him all the best in his future endeavors.”

Prior to joining USU’s senior leadership team, Dr. Billingsley served as Dean and Professor of the College of Nursing and Health Sciences. Earlier in her career, she served at Grand Canyon University, including as Chair of the Doctor of Nursing Practice program. She holds a Doctor of Nursing Practice and Master of Nursing in Family Nurse Practitioner from Grand Canyon University and a Bachelor of Science in Nursing from Arizona State University.

“I am honored to have the opportunity to serve as President of both USU and AU,” said Dr. Billingsley. “I have had the privilege of working alongside our faculty, staff and students and have seen firsthand their commitment to academic excellence and student success. I look forward to building on that foundation as we continue to advance the Universities’ mission and provide accessible, high-quality educational opportunities for our students.”

About Aspen Group, Inc.

Aspen Group, Inc. is an education technology holding company that leverages its infrastructure and expertise to allow its two universities, United States University and Aspen University, to deliver on the vision of making college affordable again. For more information, visit www.aspu.com.

Contact Information:

Hayden IR
Kimberly Rogers
(385) 831-7337
Kim@HaydenIR.com

NOT FOR DISTRIBUTION IN THE UNITED STATES. FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAW.

The final short form prospectus is accessible through SEDAR+

CALGARY, Alberta, Sept. 23, 2026 (GLOBE NEWSWIRE) — Alaris Equity Partners Income Trust (“Alaris” or the “Trust“) (TSX: AD.UN) is pleased to announce today that it has filed, and obtained a receipt for, a final short form prospectus (the “Prospectus“) in each of the provinces of Canada, other than Québec, with respect to the previously announced bought deal offering of 4,465,000 trust units of the Trust (“Units“) at a price of $22.40 per Unit for aggregate gross proceeds of approximately $100 million (the “Offering“) through a syndicate of underwriters (the “Underwriters“) led by CIBC Capital Markets, Acumen Capital Finance Partners Limited and National Bank of Canada Capital Markets. The Trust has also granted the Underwriters an option to purchase up to an additional 669,750 Units, on the same terms and conditions as the Offering, exercisable in whole or in part at any time and from time to time, up to 30 days following closing of the Offering to cover over-allotments and for market stabilization purposes, for additional gross proceeds of up to approximately $15 million.

Access to the Prospectus and any amendment thereto is provided in accordance with securities legislation relating to procedures for providing access to a prospectus and any amendment thereto. The Prospectus and any amendment thereto is accessible on SEDAR+ at www.sedarplus.ca. An electronic or paper copy of the Prospectus and any amendment thereto may be obtained, without charge, by contacting CIBC Capital Markets, 161 Bay Street, 5th floor, Toronto, Ontario M5J 2S8, by telephone at 1-416-956-6378 or by email at mailbox.canadianprospectus@cibc.com, from Acumen Capital Finance Partners Limited at info@acumencapital.com or from National Bank of Canada Capital Markets by telephone at 416-869-8414 or by email at nbf-syndication@bnc.ca, by providing the contact with an email address or address, as applicable. Prospective investors should read the Prospectus in its entirety before making an investment decision.

The closing of the Offering is expected to occur on September 28, 2026, subject to customary closing conditions.

ABOUT ALARIS

Alaris’ investment and investing activity refers to providing, through the wholly-owned subsidiaries of Alaris (the “Acquisition Entities“), structured equity to private companies (“Partners“) to meet their business and capital objectives, which includes management buyouts, dividend recapitalization, growth and acquisitions. Alaris achieves this by investing its unitholder capital, as well as debt, through the Acquisition Entities, in exchange for distributions, dividends or interest (collectively, “Distributions“) as well as capital appreciation on both preferred and common equity. The principal objective is to generate predictable cash flows for distribution payments to its unitholders while growing net book value through returns from capital appreciation. Distributions, other than common equity Distributions, from the Partners are adjusted annually based on the percentage change of a “top-line” financial performance measure such as gross margin or same store sales and rank in priority to common equity position.

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking information and statements within the meaning of applicable securities laws. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking information or statements. In particular, but without limiting the forgoing, this press release contains forward-looking statements concerning the Underwriters’ over-allotment option and the expected closing date of the Offering. Although Alaris believes that the expectations reflected in these forward-looking statements are reasonable, undue reliance should not be placed on them because Alaris can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. The forward-looking statements contained in this press release are made as of the date hereof and Alaris undertakes no obligations to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

For further information please contact:

ir@alarisequity.com
P: (403) 260-1457
Alaris Equity Partners Income Trust
Suite 250, 333 24th Avenue S.W.
Calgary, Alberta T2S 3E6
www.alarisequitypartners.com

MUNCIE, Ind., Sept. 23, 2026 (GLOBE NEWSWIRE) — First Merchants Corporation (Nasdaq: FRME) (the “Company”) today announced the pricing of its offering of $100 million of its 6.750% Fixed-to-Floating Rate Subordinated Notes due 2036 (the “Notes”) in a registered public offering (the “Offering”). The Notes will initially bear interest at 6.750% per annum from and including September 25, 2026 to, but excluding, October 1, 2031, with interest payable semiannually in arrears commencing on April 1, 2027. Commencing October 1, 2031, the interest rate on the Notes will reset quarterly to a floating rate per annum equal to a benchmark rate that is expected to be Three-Month Term SOFR (which is defined in the Notes) plus 202 basis points, with interest payable quarterly in arrears.

The Company may redeem the Notes, in whole or in part, on October 1, 2031 and on any interest payment date thereafter at a price equal to 100% of the principal amount of the Notes being redeemed plus accrued and unpaid interest thereon. The Notes will mature on October 1, 2036 if they are not earlier redeemed.

The Company expects to close the Offering, subject to the satisfaction of customary closing conditions, on or about September 25, 2026. The Company intends to use the net proceeds from this offering for general corporate purposes, including, but not limited to, the repurchase of its common shares. The Notes are intended to qualify as Tier 2 capital for regulatory purposes.

Piper Sandler is acting as the sole book-running manager for the Offering. Keefe, Bruyette & Woods, A Stifel Company, Hovde Group and Brean Capital are serving as co-managers.

This press release is neither an offer to sell nor a solicitation of an offer to purchase any securities of the Company. There will be no sale of securities in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any offer to sell or solicitation of an offer to purchase securities of the Company will be made only pursuant to a prospectus supplement and prospectus filed with the Securities and Exchange Commission (the “SEC”). The Company has filed a registration statement (including a prospectus) (File No. 333-298983) and a preliminary prospectus supplement with the SEC for the Offering to which this press release relates. Before making an investment decision, you should read the prospectus and preliminary prospectus supplement and other documents that the Company has filed with the SEC for additional information about the Company and the Offering.

Copies of the preliminary prospectus supplement and accompanying base prospectus relating to the Offering can be obtained without charge by visiting the SEC’s website at www.sec.gov, or may be obtained by emailing Piper Sandler & Co. at fsg-dcm@psc.com.

About First Merchants Corporation

First Merchants Corporation is a financial holding company headquartered in Muncie, Indiana. The Corporation has one full-service bank charter, First Merchants Bank. The Bank also operates as First Merchants Private Wealth Advisors (as a division of First Merchants Bank).

First Merchants Corporation’s common stock is traded on the NASDAQ Global Select Market System under the symbol FRME. Quotations are carried in daily newspapers and can be found on the company’s Internet web page (http://www.firstmerchants.com).

FIRST MERCHANTS and the Shield Logo are federally registered trademarks of First Merchants Corporation.

Forward-Looking Statements

This press release and any other written or oral statements made by us from time to time may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements may be identified by reference to a future period or periods, or by the use of forward-looking terminology, such as “believe”, “continue”, “pattern”, “estimate”, “project”, “intend”, “anticipate”, “expect” and similar expressions or future or conditional verbs such as “will”, “would”, “should”, “could”, “might”, “can”, “may”, or similar expressions. These forward-looking statements include (i) statements of the Company’s goals, intentions, and expectations; (ii) statements regarding the Company’s business plan and growth strategies; (iii) statements regarding the asset quality of the Company’s loan and investment portfolios; and (iv) estimates of the Company’s risks and future costs and benefits.

All forward-looking statements are subject to risks, uncertainties, and other factors, many of which are beyond our control, that may cause the actual results, performance, or achievements of the Company to differ materially from any results expressed or implied by such forward-looking statements. Such factors include, among others: (i) fluctuations in market rates of interest and loan and deposit pricing, which could negatively affect our net interest margin, asset valuations, and expense expectations; (ii) adverse changes in the economy, which might affect our business prospects and could cause credit-related losses and expenses; (iii) the impacts of epidemics, pandemics, or other infectious disease outbreaks; (iv) the impacts related to or resulting from recent bank failures or adverse developments at other banks on general investor sentiment regarding the stability and liquidity of banks; (v) adverse developments in our loan and investment portfolios; (vi) competitive factors in the banking industry, such as the trend towards consolidation in our market; (vii) changes in the banking legislation or the regulatory requirements of federal and state agencies applicable to bank holding companies and banks like our affiliate bank; (viii) acquisitions of other businesses by us and integration of such acquired businesses; (ix) changes in market, economic, operational, liquidity, credit, and interest rate risks associated with our business; and (x) the continued availability of earnings and excess capital sufficient for the lawful and prudent declaration and payment of cash dividends.

Actual results, performance or achievement could differ materially from those contained in these forward-looking statements for a variety of reasons, including, without limitation, those discussed under “Risk Factors” in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 25, 2026, and other factors discussed in the filings we make with the SEC.

All forward-looking statements attributable to the Company are expressly qualified in their entirety by these cautionary statements. Forward-looking statements speak only as of the date on which such statements are made. Except as required by law, we disclaim any obligation to update these forward-looking statements, whether as a result of new information, future events, or otherwise. There is no assurance that future results, levels of activity, performance, or goals will be achieved.

For more information, contact:
First Merchants Corporation
Nicole M. Weaver, First Vice President and Director of Corporate Administration
765-521-7619
http://www.firstmerchants.com

SOURCE: First Merchants Corporation, Muncie, Indiana

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.